The role of the proteasome in AML

C. M. Csizmar, D. H. Kim, Z. Sachs

Research output: Contribution to journalReview article

17 Citations (Scopus)

Abstract

Acute myeloid leukemia (AML) is deadly hematologic malignancy. Despite a well-characterized genetic and molecular landscape, targeted therapies for AML have failed to significantly improve clinical outcomes. Over the past decade, proteasome inhibition has been demonstrated to be an effective therapeutic strategy in several hematologic malignancies. Proteasome inhibitors, such as bortezomib and carfilzomib, have become mainstays of treatment for multiple myeloma and mantle cell lymphoma. In light of this success, there has been a surge of literature exploring both the role of the proteasome and the effects of proteasome inhibition in AML. Pre-clinical studies have demonstrated that proteasome inhibition disrupts proliferative cell signaling pathways, exhibits cytotoxic synergism with other chemotherapeutics and induces autophagy of cancer-related proteins. Meanwhile, clinical trials incorporating bortezomib into combination chemotherapy regimens have reported a range of responses in AML patients, with complete remission rates >80% in some cases. Taken together, this preclinical and clinical evidence suggests that inhibition of the proteasome may be efficacious in this disease. In an effort to focus further investigation into this area, these recent studies and their findings are reviewed here.

Original languageEnglish (US)
Pages (from-to)e503
JournalBlood cancer journal
Volume6
Issue number12
DOIs
StatePublished - Dec 2 2016

Fingerprint

Proteasome Endopeptidase Complex
Acute Myeloid Leukemia
Hematologic Neoplasms
Molecular Targeted Therapy
Mantle-Cell Lymphoma
Proteasome Inhibitors
Combination Drug Therapy
Multiple Myeloma
Clinical Trials
Therapeutics
Neoplasms
Bortezomib

Cite this

The role of the proteasome in AML. / Csizmar, C. M.; Kim, D. H.; Sachs, Z.

In: Blood cancer journal, Vol. 6, No. 12, 02.12.2016, p. e503.

Research output: Contribution to journalReview article

Csizmar, C. M. ; Kim, D. H. ; Sachs, Z. / The role of the proteasome in AML. In: Blood cancer journal. 2016 ; Vol. 6, No. 12. pp. e503.
@article{f43a694a56dd491689ff228e7d927317,
title = "The role of the proteasome in AML",
abstract = "Acute myeloid leukemia (AML) is deadly hematologic malignancy. Despite a well-characterized genetic and molecular landscape, targeted therapies for AML have failed to significantly improve clinical outcomes. Over the past decade, proteasome inhibition has been demonstrated to be an effective therapeutic strategy in several hematologic malignancies. Proteasome inhibitors, such as bortezomib and carfilzomib, have become mainstays of treatment for multiple myeloma and mantle cell lymphoma. In light of this success, there has been a surge of literature exploring both the role of the proteasome and the effects of proteasome inhibition in AML. Pre-clinical studies have demonstrated that proteasome inhibition disrupts proliferative cell signaling pathways, exhibits cytotoxic synergism with other chemotherapeutics and induces autophagy of cancer-related proteins. Meanwhile, clinical trials incorporating bortezomib into combination chemotherapy regimens have reported a range of responses in AML patients, with complete remission rates >80{\%} in some cases. Taken together, this preclinical and clinical evidence suggests that inhibition of the proteasome may be efficacious in this disease. In an effort to focus further investigation into this area, these recent studies and their findings are reviewed here.",
author = "Csizmar, {C. M.} and Kim, {D. H.} and Z. Sachs",
year = "2016",
month = "12",
day = "2",
doi = "10.1038/bcj.2016.112",
language = "English (US)",
volume = "6",
pages = "e503",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - The role of the proteasome in AML

AU - Csizmar, C. M.

AU - Kim, D. H.

AU - Sachs, Z.

PY - 2016/12/2

Y1 - 2016/12/2

N2 - Acute myeloid leukemia (AML) is deadly hematologic malignancy. Despite a well-characterized genetic and molecular landscape, targeted therapies for AML have failed to significantly improve clinical outcomes. Over the past decade, proteasome inhibition has been demonstrated to be an effective therapeutic strategy in several hematologic malignancies. Proteasome inhibitors, such as bortezomib and carfilzomib, have become mainstays of treatment for multiple myeloma and mantle cell lymphoma. In light of this success, there has been a surge of literature exploring both the role of the proteasome and the effects of proteasome inhibition in AML. Pre-clinical studies have demonstrated that proteasome inhibition disrupts proliferative cell signaling pathways, exhibits cytotoxic synergism with other chemotherapeutics and induces autophagy of cancer-related proteins. Meanwhile, clinical trials incorporating bortezomib into combination chemotherapy regimens have reported a range of responses in AML patients, with complete remission rates >80% in some cases. Taken together, this preclinical and clinical evidence suggests that inhibition of the proteasome may be efficacious in this disease. In an effort to focus further investigation into this area, these recent studies and their findings are reviewed here.

AB - Acute myeloid leukemia (AML) is deadly hematologic malignancy. Despite a well-characterized genetic and molecular landscape, targeted therapies for AML have failed to significantly improve clinical outcomes. Over the past decade, proteasome inhibition has been demonstrated to be an effective therapeutic strategy in several hematologic malignancies. Proteasome inhibitors, such as bortezomib and carfilzomib, have become mainstays of treatment for multiple myeloma and mantle cell lymphoma. In light of this success, there has been a surge of literature exploring both the role of the proteasome and the effects of proteasome inhibition in AML. Pre-clinical studies have demonstrated that proteasome inhibition disrupts proliferative cell signaling pathways, exhibits cytotoxic synergism with other chemotherapeutics and induces autophagy of cancer-related proteins. Meanwhile, clinical trials incorporating bortezomib into combination chemotherapy regimens have reported a range of responses in AML patients, with complete remission rates >80% in some cases. Taken together, this preclinical and clinical evidence suggests that inhibition of the proteasome may be efficacious in this disease. In an effort to focus further investigation into this area, these recent studies and their findings are reviewed here.

UR - http://www.scopus.com/inward/record.url?scp=85032684604&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032684604&partnerID=8YFLogxK

U2 - 10.1038/bcj.2016.112

DO - 10.1038/bcj.2016.112

M3 - Review article

C2 - 27911437

AN - SCOPUS:85032684604

VL - 6

SP - e503

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 12

ER -